Physiomics plc announced that it has been awarded a first contract by new client Numab Therapeutics ("Numab"). Numab is an exciting young biopharmaceutical company based in Zurich, Switzerland which is developing multi-specific biotherapeutics for chronic inflammation and cancer.  Physiomics has recent significant experience of the mathematical modelling of multi-specific pharmaceuticals which it will bring to bear on an undisclosed Numab compound in this project that is expected to last around three months.